Drug intelligence / Profile preview

Tobramycin Cyclops®

Development stage
Preclinical
Lead developer
PureIMS
Modality
Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration
Inhalation
01

Overview

Tobramycin Cyclops® is a dry powder inhaler (DPI) formulation of the aminoglycoside antibiotic tobramycin, developed by PureIMS for the treatment of chronic pulmonary *Pseudomonas aeruginosa* infections. It utilizes the proprietary Cyclops® technology, a high-dose, disposable, and pre-filled inhaler designed for efficient pulmonary delivery. Tobramycin acts as a bacterial protein synthesis inhibitor by binding to the 30S ribosomal subunit, which disrupts the translation process and leads to bacterial cell death. This formulation is specifically intended for patients with cystic fibrosis and bronchiectasis, providing a more convenient and faster administration alternative to traditional nebulized tobramycin therapies while achieving high lung concentrations with minimal systemic exposure.

Brand names
Tobramycin Cyclops®
Other names
Tobramycin CyclopsTobramycin DPITobramycin DPI (PureIMS)
02

Targets

H69 (Helix 69 of the 23S ribosomal RNA)30S A-site (Bacterial ribosomal 30S A-site)

Beyond the preview

Go deeper on Tobramycin Cyclops®.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tobramycin Cyclops®.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call